Kiniksa Pharmaceuticals L... (KNSA)

NASDAQ: KNSA · Real-Time Price · USD

27.79

0.82 (3.04%)

At close: May 01, 2025, 3:59 PM

27.74

-0.18%

After-hours: May 01, 2025, 04:20 PM EDT

3.04% (1D)

Bid	27.61
Market Cap	2.03B
Revenue (ttm)	481.17M
Net Income (ttm)	-2.9M
EPS (ttm)	-0.24
PE Ratio (ttm)	-115.79
Forward PE	21.73
Analyst	Buy

Ask	27.96
Volume	957,099
Avg. Volume (20D)	665,480
Open	26.86
Previous Close	26.97
Day's Range	26.86 - 28.11
52-Week Range	17.38 - 28.15
Beta	0.31

About KNSA

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclo...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date May 25, 2018

Employees 315

Stock Exchange NASDAQ

Ticker Symbol KNSA

Website https://www.kiniksa.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for KNSA stock is "Buy." The 12-month stock price forecast is $37.5, which is an increase of 34.94% from the latest price.

Stock Forecasts

Earnings Surprise

Kiniksa Pharmaceuticals has released their quartely earnings on Apr 29, 2025:

Revenue of $137.78M exceeds estimates by $6.08M, with 72.54% YoY growth.

EPS of 0.11 misses estimates by -0.17, with 144.00% YoY growth.

Why Price Moved

2 days ago

+20.54%

Kiniksa Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription

6 months ago

-15.66%

Kiniksa Pharmaceuticals shares are trading lower after the company announced worse-than-expected Q3 financial results.

News

2 days ago · seekingalpha.com

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q1 2025 Results Conference Call April 29, 2025 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman...

1 day ago · zacks.com

Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.02 per share.

3 weeks ago · zacks.com

Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?

Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Krystal Biotech, Inc. (KRYS) have performed compared to their sector so far this year.

3 weeks ago · zacks.com

Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know

The consensus price target hints at a 64.8% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...

1 month ago · zacks.com

How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%

The average of price targets set by Wall Street analysts indicates a potential upside of 58.6% in Kiniksa Pharmaceuticals (KNSA). While the effectiveness of this highly sought-after metric is question...

1 month ago · fool.com

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable.

1 month ago · zacks.com

Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock

Kiniksa Pharmaceuticals (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

1 month ago · zacks.com

Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?

Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be ...

1 month ago · zacks.com

Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High?

The consensus price target hints at a 73.4% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...

2 months ago · seekingalpha.com

Big Pipeline Updates From Kiniksa Pharmaceuticals

Load More News